|
41
|
Product specific BE guideline |
Montelukast sodium Chewable Tablet, 5 mg, 4 mg_生體相等性試驗指導原則
|
2025-09-24 |
|
42
|
Product specific BE guideline |
Montelukast sodium Oral Granules 4 mg_生體相等性試驗指導原則
|
2025-09-24 |
|
43
|
Product specific BE guideline |
Montelukast sodium Tablets_生體相等性試驗指導原則
|
2025-09-24 |
|
44
|
Product specific BE guideline |
Nebivolol hydrochloride tablet_生體相等性試驗指導原則
|
2025-09-24 |
|
45
|
Product specific BE guideline |
Silodosin Capsule_生體相等性試驗指導原則
|
2025-09-24 |
|
46
|
Product specific BE guideline |
Sitagliptin phosphate_Metformin HCl Tablet_生體相等性試驗指導原則
|
2025-09-24 |
|
47
|
Product specific BE guideline |
Sultamicillin tablet_生體相等性試驗指導原則
|
2025-09-24 |
|
48
|
Product specific BE guideline |
Tamsulosin PR Tablet_生體相等性試驗指導原則
|
2025-09-24 |
|
49
|
PK/PD |
於NDA與IND的生體可用率試驗之研發策略指導原則
|
2025-09-24 |
|
50
|
Quality |
開發新型冠狀病毒緊急使用授權之單株抗體藥品的品質法規考量重點
|
2025-09-24 |
